Filana Therapeutics financials
$0.5720−3.75%
Close Nov 4, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$9.4M | -$11.2M |
| Net income | -$8.6M | -$10.3M |
| Net margin | — | — |
| Diluted EPS | $-0.18 | $-0.21 |
| EBITDA | -$9.1M | -$10.9M |
| Operating cash flow | -$3.9M | -$8.9M |
| Free cash flow | -$3.9M | -$8.9M |
| Diluted shares | 48.3M | 49.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $82.7M | $86.6M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $103.9M | $108.4M |
| Total liabilities | $40.3M | $40.2M |
| Shareholders' equity | $63.6M | $68.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology